(Beijing, 28 September 2020) – China Renaissance Holdings Limited ("China Renaissance") ("China Renaissance", stock code: 1911.HK) today announced that it served as the exclusive financial advisor for InventisBio Inc. ("InvestisBio"), a clinical stage biotech company dedicated to the discovery and development of novel therapeutics against cancer and metabolic diseases, in its US$147 million Series D financing round.  

InvestisBio's Series D financing round was led by Hillhouse affiliate GL Ventures. Other investors included Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partners China, Dyee Capital and E-Fund Capital. Existing shareholders, including Lilly Asia Ventures, OrbiMed Asia, Pudong Innotek, AdvanTech Capital and CMB International also participated in the round.     

InventisBio is a dynamic and fast-growing global biotech company with multiple therapeutic agents at various clinical stages. The company, which has offices in China and the United States, was founded by a group of scientists with extensive research & development ("R&D") and management experience gained from leading multinational pharmaceutical companies.     

InventisBio will use the new funding to accelerate the development of its candidates into phase 2 clinical trials in China and United States for breast cancer and gout. The company will also use the investment to further expand its R&D facility and staff and support its in-licensing product development.     

Kevin Xie, Managing Director and Head of Healthcare and Life Sciences of China Renaissance, said: "The successful Series D financing is an important milestone for InventisBio, which follows last year's Series C financing, and is a testament to the company's robust growth momentum. China Renaissance is honored to have served as the exclusive financial advisor for both rounds as we deepen our partnership with the company. We continue to be impressed by InventisBio's talented management team, its world-class scientists and technical experts and the company's ability to execute on its growth strategy to develop potentially game-changing treatments."